



Drug Quantity Management – Per Rx Antiepileptics – Xcopri® (cenobamate tablets)

Table of Contents

National Formulary Medical Necessity	1
Conditions Not Covered.....	2
Background.....	2
References	3
Revision History.....	3

Product Identifier(s)

Effective 1/1/23 to 2/6/23: 109033

Effective 2/7/23: 81552

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

This Drug Quantity Management program has been developed to promote dose consolidation, to prevent stockpiling and waste, and to address potential order entry error of Xcopri. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Drug Quantity Limits

Product	Strength and Form	Maximum Quantity per Rx
Xcopri® (cenobamate tablets)	50 mg tablets	30 tablets
	100 mg tablets	30 tablets
	150 mg tablets	30 tablets
	200 mg tablets	30 tablets
	Titration Blister Packs	
	12.5 mg/25 mg (contains 14 tablets of each strength, 12.5 mg and 25 mg)	28 tablets
	50 mg/100 mg (contains 14 tablets of each strength, 50 mg and 100 mg)	28 tablets

	150 mg/200 mg (contains 14 tablets of each strength, 150 mg and 200 mg)	28 tablets
	Maintenance Blister Packs	
	250 mg/day (contains 28 x 100-mg tablets and 28 x 150-mg tablets)	56 tablets
	350 mg/day (contains 28 x 150-mg tablets and 28 x 200-mg tablets)	56 tablets

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

Xcopri 50 mg tablets

No overrides recommended.

Xcopri 100 mg tablets

No overrides recommended.

Xcopri 150 mg tablets

1. If the individual is taking a daily dose of 300 mg, approve 60 tablets per dispensing.

Xcopri 200 mg tablets

1. If the individual is taking a daily dose of 400 mg, approve 60 tablets per dispensing.

Xcopri Titration Blister Packs (12.5 mg/25 mg tablets, 50 mg/100 mg tablets, 150 mg/200 mg tablets)

No overrides recommended.

Xcopri Maintenance Blister Packs (250 mg/day and 350 mg/day)

No overrides recommended.

Conditions Not Covered

Any other exception is considered not medically necessary

Background

Overview

Xcopri is indicated for the treatment of **partial-onset seizures** in adults.¹

Dosing

Xcopri is administered orally once daily.¹ The recommended dosage and titration schedule is provided in Table 1. The maximum dose is 400 mg/day. Tablets should not be not crushed or chewed.

Table 1. Recommended Dosing for Partial-Onset Seizures in Adults.¹

Initial Dosage	
Week 1 and 2	12.5 mg QD
Titration Regimen	
Weeks 3 and 4	25 mg QD
Weeks 5 and 6	50 mg QD
Weeks 7 and 8	100 mg QD
Weeks 9 and 10	150 mg QD
Maintenance Dosage	
Week 11 and thereafter	200 mg QD
Maximum Dosage	
If needed based on clinical response and tolerability, dose may be increased above 200 mg by increments of 50 mg once daily every 2 weeks to 400 mg.	400 mg QD

QD – Once daily.

Availability

Xcopri is supplied in bottles containing 30 tablets in the following strengths: 50 mg, 100 mg, 150 mg, and 200 mg.¹ Titration blister packs (28-days) are available in the following strengths: 12.5 mg/25 mg (12.5 mg for 14 days and 25 mg for 14 days), 50 mg/100 mg (50 mg for 14 days and 100 mg for 14 days), and 150 mg/200 mg (150 mg for 14 days and 200 mg for 14 days). Maintenance blister packs (28-days) are available in the following strengths: 250 mg/day (28 x 100-mg tablets and 28 x 150-mg tablets) and 350 mg/day (28 x 150-mg tablets and 28 x 200-mg tablets).

References

1. Xcopri® tablets [prescribing information]. Paramus, NJ: SK Life Science; April 2021.

Revision History

Type of Revision	Summary of Changes	Approval Date
Annual Revision	Xcopri Titration Blister Packs (12.5 mg/25 mg, 50 mg/100 mg, and 150 mg/200 mg) maximum quantity per Rx was changed to 28 tablets, previously 56 tablets.	04/20/2022

“Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.